세계의 저분자 이노베이터 CDMO 시장 : 산업 규모, 점유율, 동향, 기회 및 예측 - 제품별, 스테이지 유형별, 고객 유형별, 치료 분야별, 지역별, 경쟁별(2020-2030년)

Small Molecule Innovator CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Stage Type, By Customer Type, By Therapeutic Area, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,497,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,940,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,550,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 저분자 이노베이터 개발 및 제조 위탁생산(CDMO) 시장은 2024년 482억 6,000만 달러로 평가되었습니다. 2030년까지 722억 6,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 6.96%를 보일 것으로 예측됩니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	482억 6,000만 달러
시장 규모 : 2030년	722억 6,000만 달러
CAGR : 2025-2030년	6.96%
급성장 부문	저분자 API
최대 시장	북미

이 시장은 제약 및 바이오 의약품 산업의 중요한 부분을 형성하고 있으며, 의약품 개발 및 제조에 필수적인 서비스를 제공합니다. 저분자 화합물(의약품 유효성분(API)으로 사용되는 저분자 화합물)은 다양한 치료제의 제조에 널리 사용되고 있습니다. 저분자 전문 CDMO는 의약품 개발, 공정 최적화, 스케일업, 제조, 약사 지원 등 엔드 투 엔드 솔루션을 제공합니다.

저분자 이노베이터 CDMO는 저분자 원료의약품 및 완제의약품의 초기 개발부터 상업적 생산에 이르는 종합적인 서비스를 통해 제약회사 및 생명공학기업을 지원하는 전문 기업입니다.

시장 성장 촉진요인

아웃소싱 트렌드 증가

저분자 혁신 CDMO 시장에서의 아웃소싱 트렌드는 의약품 개발 및 자원 배분을 최적화하기 위한 제약 및 생명공학 기업들의 전략적 대응입니다. 아웃소싱을 통해 기업은 업무 효율성을 개선하고, 전문 지식을 활용하며, 시장 출시 시간을 단축할 수 있습니다.

CDMO와 협력하면 큰 이점을 얻을 수 있습니다. CDMO는 제제 개발, 공정 최적화, 분석 시험, 규제 준수에 대한 깊은 지식을 보유하고 있으며, 저분자 치료제의 성공적인 개발에 필수적인 역량을 보유하고 있습니다. 이러한 기능을 아웃소싱함으로써 제약회사는 최첨단 기술과 검증된 프로세스의 혜택을 누리면서 내부 역량 구축에 따른 막대한 투자를 피할 수 있습니다.

또한, 현대의 의약품 개발은 복잡하고 다학제적이기 때문에 CDMO가 제공할 수 있는 민첩성과 규제에 대한 통찰력을 필요로 합니다. 이러한 파트너십을 통해 혁신 기업은 연구 및 임상 개발과 같은 핵심 역량에 집중할 수 있으며, 제조 및 운영 업무는 숙련된 파트너에게 맡길 수 있습니다.

시장의 과제

지적재산권(IP) 보호

저분자 이노베이터 CDMO 시장에서 중요한 과제는 지적재산권 보호입니다. 혁신 기업들은 새로운 화합물이나 독자적인 제조 공정을 개발하기 위해 연구개발에 많은 투자를 하는 경우가 많으며, CDMO와 파트너십을 맺을 때 화학 구조, 합성 방법, 분석 기술 등 기밀 데이터를 공유해야 합니다.

이러한 상호 작용은 지적 재산권 유출 및 무단 공개와 관련된 위험을 초래할 수 있습니다. 이러한 우려를 줄이기 위해 기업은 일반적으로 독점 정보의 공유, 사용 및 보호에 관한 조건을 명시한 엄격한 비밀유지계약(비밀유지계약, NDA 등)을 체결합니다. 이러한 법적 보호 조치는 개발 라이프사이클 전반에 걸쳐 신뢰를 유지하고 경쟁 우위를 확보하는 데 필수적입니다.

시장 동향

개인 맞춤형 의료와 틈새 치료의 등장

개인 맞춤형 의료와 틈새 치료는 개별 환자 프로파일에 기반한 맞춤형 치료 전략과 독특한 건강 상태를 가진 특정 집단을 타겟팅하는 데 초점을 맞추면서 의약품의 환경을 재구성하고 있습니다.

그 중 저분자 혁신 신약 CDMO 시장은 점점 더 중요한 역할을 하고 있습니다. 맞춤의료는 환자의 유전적 특성, 생활습관, 질병 특이적 바이오마커에 맞추어 치료 전략을 조정하여 치료 결과를 향상시키려는 것입니다. 혁신 기업들은 이러한 고유한 마커를 표적으로 하는 저분자 의약품을 개발하여 효능을 개선하고 부작용을 줄이는 데 주력하고 있습니다.

CDMO는 이러한 치료제를 시장에 출시하는 데 있어 중요한 역할을 담당하고 있습니다. 분자생물학, 약리유전체학, 분석화학에 대한 전문지식을 갖춘 CDMO는 맞춤형 치료제의 개발 및 제조를 지원할 수 있습니다. 이러한 역량은 맞춤 치료에 필요한 정확성, 확장성 및 규제 준수를 보장하는 데 필수적입니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 저분자 이노베이터 CDMO 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품별(저분자 API, 저분자 의약품)
  • 스테이지 유형별(전임상, 임상, 상업)
  • 고객 유형별(의약품, 바이오테크놀러지)
  • 치료 분야별(순환기 질환, 종양학, 호흡기 질환, 신경학, 대사 질환, 감염증, 기타)
  • 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
  • 기업별(2024년)
• 제품 시장 맵
  • 제품별
  • 스테이지 유형별
  • 고객 유형별
  • 치료 분야별
  • 지역별

제6장 북미의 저분자 이노베이터 CDMO 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 저분자 이노베이터 CDMO 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 저분자 이노베이터 CDMO 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주

제9장 남미의 저분자 이노베이터 CDMO 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 저분자 이노베이터 CDMO 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 아랍에미리트
  • 사우디아라비아
  • 남아프리카공화국

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 개발
• 최근 동향

제13장 임상시험 분석

제14장 경쟁 구도

• Lonza Group AG
• Thermo Fisher Scientific Inc
• Cambrex Corporation
• Catalent, Inc
• Siegfried Holding AG
• Recipharm AB
• Corden Pharma GmbH
• Boehringer Ingelheim GmbH
• Piramal Pharma Solutions
• LABCORP HOLDINGS INC.

제15장 전략적 제안

제16장 회사 소개 및 면책조항

LSH

영문 목차

영문목차

Global Small Molecule Innovator Contract Development and Manufacturing Organization (CDMO) market was valued at USD 48.26 billion in 2024 and is projected to reach USD 72.26 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.96% during the forecast period.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 48.26 Billion
Market Size 2030	USD 72.26 Billion
CAGR 2025-2030	6.96%
Fastest Growing Segment	Small Molecule API
Largest Market	North America

This market forms a vital part of the pharmaceutical and biopharmaceutical industries, offering essential services in drug development and manufacturing. Small molecules-low molecular weight compounds used as active pharmaceutical ingredients (APIs)-are widely employed in the production of various therapeutic drugs. CDMOs specializing in small molecules provide end-to-end solutions, including drug development, process optimization, scale-up, manufacturing, and regulatory support.

Small Molecule Innovator CDMOs are specialized entities that support pharmaceutical and biotech companies through comprehensive services that span from early-stage development to commercial production of small molecule APIs and finished drug products.

Market Growth Drivers

Increasing Trend Toward Outsourcing

The growing trend of outsourcing in the Small Molecule Innovator CDMO market is a strategic response by pharmaceutical and biotechnology companies seeking to optimize drug development and resource allocation. Outsourcing enables firms to improve operational efficiency, leverage specialized expertise, and accelerate time-to-market.

Partnering with CDMOs offers significant advantages. These organizations bring in-depth knowledge of formulation development, process optimization, analytical testing, and regulatory compliance-capabilities critical to the successful development of small molecule therapeutics. By outsourcing these functions, pharmaceutical innovators can avoid the substantial investments associated with building in-house capabilities, while still benefiting from cutting-edge technologies and proven processes.

Moreover, the complex and multidisciplinary nature of modern drug development requires agility and regulatory acumen-qualities that CDMOs are well-equipped to provide. These partnerships also allow innovator companies to maintain focus on their core strengths, such as research and clinical development, while entrusting manufacturing and operational tasks to experienced partners.

Market Challenges

Intellectual Property (IP) Protection

A key challenge in the Small Molecule Innovator CDMO market is the safeguarding of intellectual property. Innovator companies often invest heavily in R&D to create novel compounds and proprietary manufacturing processes. When entering into CDMO partnerships, they must share confidential data, including chemical structures, synthetic methodologies, and analytical techniques.

This exchange introduces risks related to IP leakage or unauthorized disclosure. To mitigate these concerns, companies typically implement strict confidentiality agreements (e.g., Non-Disclosure Agreements or NDAs) outlining terms for the sharing, usage, and protection of proprietary information. These legal safeguards are critical to maintaining trust and securing competitive advantages throughout the development lifecycle.

Market Trends

Emergence of Personalized Medicine and Niche Therapies

Personalized medicine and niche therapies are reshaping the pharmaceutical landscape by focusing on customized treatment strategies based on individual patient profiles or targeting specific populations with unique health conditions.

In this context, the Small Molecule Innovator CDMO market is playing an increasingly vital role. Personalized medicine seeks to enhance therapeutic outcomes by aligning treatment strategies with a patient's genetic characteristics, lifestyle, and disease-specific biomarkers. Innovator companies are developing small molecule drugs that target these unique markers, offering improved efficacy and reduced side effects.

CDMOs are instrumental in bringing these therapies to market. Their expertise in molecular biology, pharmacogenomics, and analytical chemistry enables them to support the development and manufacturing of tailored treatments. These capabilities are essential to ensuring the precision, scalability, and regulatory compliance required for personalized therapies.

Key Market Players

Lonza Group AG

Thermo Fisher Scientific Inc

Cambrex Corporation

Catalent, Inc

Siegfried Holding AG

Recipharm AB

Corden Pharma GmbH

Boehringer Ingelheim GmbH

Piramal Pharma Solutions

LABCORP HOLDINGS INC.

Report Scope:

In this report, the Global Small Molecule Innovator CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Small Molecule Innovator CDMO Market, By Product:

Small Molecule API

Small Molecule Drug Product

Small Molecule Innovator CDMO Market, By Stage Type:

Preclinical

Clinical

Commercial

Small Molecule Innovator CDMO Market, By Customer Type:

Pharmaceutical

Biotechnology

Small Molecule Innovator CDMO Market, By Therapeutic Area:

Cardiovascular disease

Oncology

Respiratory disorders

Neurology

Metabolic disorders

Infectious disease

Others

Small Molecule Innovator CDMO Market, By Region:

North America

• United States
• Canada
• Mexico

Europe

• Germany
• France
• United Kingdom
• Italy
• Spain

Asia-Pacific

• China
• Japan
• India
• South Korea
• Australia

South America

• Brazil
• Argentina
• Colombia

Middle East & Africa

• UAE
• Saudi Arabia
• South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Small Molecule Innovator CDMO Market.

Available Customizations:

Global Small Molecule Innovator CDMO Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Types
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Small Molecule Innovator CDMO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Small Molecule API, Small Molecule Drug Product)
  • 5.2.2. By Stage Type (Preclinical, Clinical, Commercial)
  • 5.2.3. By Customer Type (Pharmaceutical, Biotechnology)
  • 5.2.4. By Therapeutic Area (Cardiovascular disease, Oncology, Respiratory disorders, Neurology, Metabolic disorders, Infectious disease, Others)
  • 5.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.6. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Product
  • 5.3.2. By Stage Type
  • 5.3.3. By Customer Type
  • 5.3.4. By Therapeutic Area
  • 5.3.5. By Region

6. North America Small Molecule Innovator CDMO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Stage Type
  • 6.2.3. By Customer Type
  • 6.2.4. By Therapeutic Area
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Small Molecule Innovator CDMO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Stage Type
      • 6.3.1.2.3. By Customer Type
      • 6.3.1.2.4. By Therapeutic Area
  • 6.3.2. Canada Small Molecule Innovator CDMO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Stage Type
      • 6.3.2.2.3. By Customer Type
      • 6.3.2.2.4. By Therapeutic Area
  • 6.3.3. Mexico Small Molecule Innovator CDMO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Stage Type
      • 6.3.3.2.3. By Customer Type
      • 6.3.3.2.4. By Therapeutic Area

7. Europe Small Molecule Innovator CDMO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Stage Type
  • 7.2.3. By Customer Type
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Small Molecule Innovator CDMO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Stage Type
      • 7.3.1.2.3. By Customer Type
      • 7.3.1.2.4. By Therapeutic Area
  • 7.3.2. France Small Molecule Innovator CDMO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Stage Type
      • 7.3.2.2.3. By Customer Type
      • 7.3.2.2.4. By Therapeutic Area
  • 7.3.3. United Kingdom Small Molecule Innovator CDMO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Stage Type
      • 7.3.3.2.3. By Customer Type
      • 7.3.3.2.4. By Therapeutic Area
  • 7.3.4. Italy Small Molecule Innovator CDMO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Stage Type
      • 7.3.4.2.3. By Customer Type
      • 7.3.4.2.4. By Therapeutic Area
  • 7.3.5. Spain Small Molecule Innovator CDMO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Stage Type
      • 7.3.5.2.3. By Customer Type
      • 7.3.5.2.4. By Therapeutic Area

8. Asia-Pacific Small Molecule Innovator CDMO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Stage Type
  • 8.2.3. By Customer Type
  • 8.2.4. By Therapeutic Area
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Small Molecule Innovator CDMO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Stage Type
      • 8.3.1.2.3. By Customer Type
      • 8.3.1.2.4. By Therapeutic Area
  • 8.3.2. Japan Small Molecule Innovator CDMO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Stage Type
      • 8.3.2.2.3. By Customer Type
      • 8.3.2.2.4. By Therapeutic Area
  • 8.3.3. India Small Molecule Innovator CDMO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Stage Type
      • 8.3.3.2.3. By Customer Type
      • 8.3.3.2.4. By Therapeutic Area
  • 8.3.4. South Korea Small Molecule Innovator CDMO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Stage Type
      • 8.3.4.2.3. By Customer Type
      • 8.3.4.2.4. By Therapeutic Area
  • 8.3.5. Australia Small Molecule Innovator CDMO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Stage Type
      • 8.3.5.2.3. By Customer Type
      • 8.3.5.2.4. By Therapeutic Area

9. South America Small Molecule Innovator CDMO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Stage Type
  • 9.2.3. By Customer Type
  • 9.2.4. By Therapeutic Area
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Small Molecule Innovator CDMO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Stage Type
      • 9.3.1.2.3. By Customer Type
      • 9.3.1.2.4. By Therapeutic Area
  • 9.3.2. Argentina Small Molecule Innovator CDMO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Stage Type
      • 9.3.2.2.3. By Customer Type
      • 9.3.2.2.4. By Therapeutic Area
  • 9.3.3. Colombia Small Molecule Innovator CDMO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Stage Type
      • 9.3.3.2.3. By Customer Type
      • 9.3.3.2.4. By Therapeutic Area

10. Middle East and Africa Small Molecule Innovator CDMO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Stage Type
  • 10.2.3. By Customer Type
  • 10.2.4. By Therapeutic Area
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. UAE Small Molecule Innovator CDMO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Stage Type
      • 10.3.1.2.3. By Customer Type
      • 10.3.1.2.4. By Therapeutic Area
  • 10.3.2. Saudi Arabia Small Molecule Innovator CDMO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Stage Type
      • 10.3.2.2.3. By Customer Type
      • 10.3.2.2.4. By Therapeutic Area
  • 10.3.3. South Africa Small Molecule Innovator CDMO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Stage Type
      • 10.3.3.2.3. By Customer Type
      • 10.3.3.2.4. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition
• 12.2. Product Development
• 12.3. Recent Developments

13. Clinical Trial Analysis

• 13.1. Ongoing Clinical Trials
• 13.2. Completed Clinical Trials
• 13.3. Terminated Clinical Trials
• 13.4. Breakdown of Pipeline, By Development Phase
• 13.5. Breakdown of Pipeline, By Status
• 13.6. Breakdown of Pipeline, By Study Type
• 13.7. Breakdown of Pipeline, By Region
• 13.8. Clinical Trials Heat Map

14. Competitive Landscape

• 14.1. Lonza Group AG
  • 14.1.1 Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Thermo Fisher Scientific Inc
• 14.3. Cambrex Corporation
• 14.4. Catalent, Inc
• 14.5. Siegfried Holding AG
• 14.6. Recipharm AB
• 14.7. Corden Pharma GmbH
• 14.8. Boehringer Ingelheim GmbH
• 14.9. Piramal Pharma Solutions
• 14.10. LABCORP HOLDINGS INC.

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료